Completed PHASE3 INTERVENTIONAL 3-arm NCT00504933

Efficacy Study for the Symptomatic Treatment of Seasonal Allergic Rhinitis

Double-blind, Randomised, Placebo-controlled, Phase III Study Comparing the Efficacy and Safety of Bilastine 20 mg Once Daily and Cetirizine 10 mg for the Treatment of Seasonal Allergic Rhinitis.

Sponsor: Faes Farma, S.A.

Conditions Seasonal Allergic Rhinitis

Interventions Cetirizine Placebo bilastine

Updated 5 times since 2017 Last updated: Apr 4, 2012 Started: May 31, 2005 Primary completion: Nov 30, 2005 Completion: Nov 30, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Seasonal Allergic Rhinitis and is currently completed. Faes Farma, S.A. leads this study, which shows 5 recorded versions since 2005 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

May 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Faes Farma, S.A.

Data source: Faes Farma, S.A.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.